Daniel M. Schmitt - Apr 1, 2025 Form 4 Insider Report for ACTUATE THERAPEUTICS, INC. (ACTU)

Role
President, CEO and Director, Director
Signature
/s/ Paul Lytle, Attorney-in-Fact
Stock symbol
ACTU
Transactions as of
Apr 1, 2025
Transactions value $
$0
Form type
4
Date filed
4/2/2025, 01:44 PM
Previous filing
Aug 14, 2024
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ACTU Employee Stock Option (right to buy) Award $0 +66.5K $0.00 66.5K Apr 1, 2025 Common Stock 66.5K $6.70 Direct F1
transaction ACTU Employee Stock Option (right to buy) Award $0 +204K $0.00 204K Apr 1, 2025 Common Stock 204K $6.70 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Options will vest as to 25% on April 1, 2026 with the remaining 75% vesting in equal monthly installments during the 36 months following the first anniversary of the grant date.
F2 Options will vest as to 25% on August 14, 2025 with the remaining 75% vesting in equal monthly installments during the 36 months thereafter.